Abstract Objective To study the effect and related signaling pathways of ginsenoside Rb1 in the treatment of coronary artery lesion (CAL) in a mouse model of Kawasaki disease (KD). Methods BALB/c mice were randomly divided into a control group, a model group, an aspirin group, a low-dose ginsenoside Rb1 group (50 mg/kg), and a high-dose ginsenoside Rb1 group (100 mg/kg), with 12 mice in each group. All mice except those in the control group were given intermittent intraperitoneal injection of 10% bovine serum albumin to establish a mouse model of KD. The mice in the aspirin group, the low-dose ginsenoside Rb1 group, and the high-dose ginsenoside Rb1 group were given the corresponding drug by gavage for 20 days after modeling. Hematoxylin and eosin staining was used to observe the pathological changes of coronary artery tissue. ELISA was used to measure the levels of the inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in serum and coronary artery tissue. Western blot was used to measure the relative expression levels of proteins involved in the regulation of the AMPK/mTOR autophagy signaling pathway and the PI3K/Akt oxidative stress signaling pathway in coronary artery tissue. Results The observation of pathological sections showed that compared with the model group, the high-dose ginsenoside Rb1 group had significant improvement in the symptoms of vascular wall thickening, intimal edema, fiber rupture, and inflammatory infiltration of endothelial cells. Compared with the control group, the model and low-dose ginsenoside Rb1 groups had significant increases in the levels of TNF-α, IL-6, and IL-1β in serum and coronary artery tissue (P < 0.05); the model group had significant increases in the expression levels of P-AMPK/AMPK, P-mTOR/mTOR, and P-P70S6/P70S6 in coronary artery tissue (P < 0.05) and significant reductions in the expression levels of P-PI3K/PI3K, P-AKT/AKT, and P-GSK-3β/GSK-3β in coronary artery tissue (P < 0.05). Compared with the model group, the aspirin group and the high-dose ginsenoside Rb1 group had significant reductions in the levels of TNF-α, IL-6, and IL-1β (P < 0.05); the low- and high-dose ginsenoside Rb1 groups had significant reductions in the expression levels of P-AMPK/AMPK, P-mTOR/mTOR, and P-P70S6/P70S6 (P < 0.05) in a dose-dependent manner between the two groups (P < 0.05); the low-dose ginsenoside Rb1 group had no significant change in the expression level of P-PI3K/PI3K (P > 0.05) and had significant increases in the expression levels of P-AKT/AKT and P-GSK-3β/GSK-3β (P < 0.05), while the high-dose ginsenoside Rb1 group had significant increases in the relative protein expression levels of the above three proteins (P < 0.05). Compared with the low-dose ginsenoside Rb1 group, the aspirin group and the high-dose ginsenoside Rb1 group had significant reductions in the levels of TNF-α, IL-6, and IL-1β (P < 0.05); the high-dose ginsenoside Rb1 group had significant increases in the expression levels of P-PI3K/PI3K and P-AKT/AKT (P < 0.05). Conclusions Ginsenoside Rb1 can effectively alleviate CAL in a mouse model of KD in a dose-dependent manner, possibly by regulating the AMPK/mTOR/P70S6 autophagy signaling pathway to inhibit CAL inflammation and regulating the PI3K/AKT/GSK-3β oxidative stress signaling pathway to exert a biological activity of protection against coronary artery endothelial cell injury.
QI Shuang-Hui,XIAO Feng,WEI Bing et al. Value of ginsenoside Rb1 in alleviating coronary artery lesion in a mouse model of Kawasaki disease[J]. CJCP, 2020, 22(9): 1034-1040.
QI Shuang-Hui,XIAO Feng,WEI Bing et al. Value of ginsenoside Rb1 in alleviating coronary artery lesion in a mouse model of Kawasaki disease[J]. CJCP, 2020, 22(9): 1034-1040.
Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease[J]. Expert Rev Anti Infect Ther, 2010, 8(2):197-203.
[14]
Qing L, Fu J, Wu P, et al. Metformin induces the M2 macrophage polarization to accelerate the wound healing via regulating AMPK/mTOR/NLRP3 inflammasome singling pathway[J]. Am J Transl Res, 2019, 11(2):655-668.
[15]
Doble BW, Woodgett JR. GSK-3:tricks of the trade for a multi-tasking kinase[J]. J Cell Sci, 2003, 116(Pt 7):1175-1186.
[16]
Kaytor MD, Orr HT. The GSK3 beta signaling cascade and neurodegenerative disease[J]. Curr Opin Neurobiol, 2002, 12(3):275-278.
An X, Lv H, Tian J, et al. Role of the PTEN/PI3K/VEGF pathway in the development of Kawasaki disease[J]. Exp Ther Med, 2016, 11(4):1318-1322.
[20]
Onouchi Z, Ikuta K, Nagamatsu K, et al. Coronary artery aneurysms develop in weanling rabbits with serum sickness but not in mature rabbits. An experimental model for Kawasaki disease in humans[J]. Angiology, 1995, 46(8):679-687.
Barranco C. Vasculitis syndromes:Kawasaki disease is IL-1β-mediated[J]. Nat Rev Rheumatol, 2016, 12(12):693.
[28]
Lee Y, Wakita D, Dagvadorj J, et al. IL-1 signaling is critically required in stromal cells in Kawasaki disease vasculitis mouse model:role of both IL-1α and IL-1β[J]. Arterioscler Thromb Vasc Biol, 2015, 35(12):2605-2616.
[29]
Alphonse MP, Duong TT, Shumitzu C, et al. Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease[J]. J Immunol, 2016, 197(9):3481-3489.
[30]
Deretic V, Klionsky DJ. Autophagy and inflammation:a special review issue[J]. Autophagy, 2018, 14(2):179-180.
[31]
Ni N, Liu Q, Ren H, et al. Ginsenoside Rb1 protects rat neural progenitor cells against oxidative injury[J]. Molecules, 2014, 19(3):3012-3024.
Shan H, Zhang S, Wei X, et al. Protection of endothelial cells against Ang Ⅱ-induced impairment:involvement of both PPARα and PPARγ via PI3K/Akt pathway[J]. Clin Exp Hypertens, 2016, 38(7):571-577.
[35]
Xia G, Fan F, Liu M, et al. Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice[J]. Biochim Biophys Acta, 2016, 1862(9):1587-1593.
